BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 25371176)

  • 1. Wild-type KRAS inhibits oncogenic KRAS-induced T-ALL in mice.
    Staffas A; Karlsson C; Persson M; Palmqvist L; Bergo MO
    Leukemia; 2015 May; 29(5):1032-40. PubMed ID: 25371176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Notch1 gene mutations target KRAS G12D-expressing CD8+ cells and contribute to their leukemogenic transformation.
    Kong G; Du J; Liu Y; Meline B; Chang YI; Ranheim EA; Wang J; Zhang J
    J Biol Chem; 2013 Jun; 288(25):18219-27. PubMed ID: 23673656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncogenic Kras initiates leukemia in hematopoietic stem cells.
    Sabnis AJ; Cheung LS; Dail M; Kang HC; Santaguida M; Hermiston ML; Passegué E; Shannon K; Braun BS
    PLoS Biol; 2009 Mar; 7(3):e59. PubMed ID: 19296721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutant Ikzf1, KrasG12D, and Notch1 cooperate in T lineage leukemogenesis and modulate responses to targeted agents.
    Dail M; Li Q; McDaniel A; Wong J; Akagi K; Huang B; Kang HC; Kogan SC; Shokat K; Wolff L; Braun BS; Shannon K
    Proc Natl Acad Sci U S A; 2010 Mar; 107(11):5106-11. PubMed ID: 20194733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of wild-type Kras promotes activation of all Ras isoforms in oncogenic Kras-induced leukemogenesis.
    Kong G; Chang YI; Damnernsawad A; You X; Du J; Ranheim EA; Lee W; Ryu MJ; Zhou Y; Xing Y; Chang Q; Burd CE; Zhang J
    Leukemia; 2016 Jul; 30(7):1542-51. PubMed ID: 27055865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogenic Kras-induced leukemogeneis: hematopoietic stem cells as the initial target and lineage-specific progenitors as the potential targets for final leukemic transformation.
    Zhang J; Wang J; Liu Y; Sidik H; Young KH; Lodish HF; Fleming MD
    Blood; 2009 Feb; 113(6):1304-14. PubMed ID: 19066392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pdx1 expression in hematopoietic cells activates
    Walcheck MT; Nukaya M; Ranheim EA; Matkowskyj KA; Ronnekleiv-Kelly S
    Leuk Lymphoma; 2023 Jun; 64(6):1112-1122. PubMed ID: 37081806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downregulating Notch counteracts Kras
    Kong G; You X; Wen Z; Chang YI; Qian S; Ranheim EA; Letson C; Zhang X; Zhou Y; Liu Y; Rajagopalan A; Zhang J; Stieglitz E; Loh M; Hofmann I; Yang D; Zhong X; Padron E; Zhou L; Pear WS; Zhang J
    Leukemia; 2019 Mar; 33(3):671-685. PubMed ID: 30206308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nras Q61R/+ and Kras-/- cooperate to downregulate Rasgrp1 and promote lympho-myeloid leukemia in early T-cell precursors.
    Wen Z; Yun G; Hebert A; Kong G; Ranheim EA; Finn R; Rajagoplan A; Li S; Zhou Y; Yu M; Damnernsawad A; Roose JP; Coon JJ; Wen R; Wang D; Zhang J
    Blood; 2021 Jun; 137(23):3259-3271. PubMed ID: 33512434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncogenic
    Osswald L; Hamarsheh S; Uhl FM; Andrieux G; Klein C; Dierks C; Duquesne S; Braun LM; Schmitt-Graeff A; Duyster J; Boerries M; Brummer T; Zeiser R
    Mol Cancer Res; 2021 Sep; 19(9):1596-1608. PubMed ID: 34088868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NOX2 inhibition reduces oxidative stress and prolongs survival in murine KRAS-induced myeloproliferative disease.
    Aydin E; Hallner A; Grauers Wiktorin H; Staffas A; Hellstrand K; Martner A
    Oncogene; 2019 Feb; 38(9):1534-1543. PubMed ID: 30323311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of Flt3⁺CD150⁻ myeloid progenitors in adult mouse bone marrow that harbor T lymphoid developmental potential.
    Chi AW; Chavez A; Xu L; Weber BN; Shestova O; Schaffer A; Wertheim G; Pear WS; Izon D; Bhandoola A
    Blood; 2011 Sep; 118(10):2723-32. PubMed ID: 21791413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus.
    Li Q; Haigis KM; McDaniel A; Harding-Theobald E; Kogan SC; Akagi K; Wong JC; Braun BS; Wolff L; Jacks T; Shannon K
    Blood; 2011 Feb; 117(6):2022-32. PubMed ID: 21163920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS.
    Qiu W; Tang SM; Lee S; Turk AT; Sireci AN; Qiu A; Rose C; Xie C; Kitajewski J; Wen HJ; Crawford HC; Sims PA; Hruban RH; Remotti HE; Su GH
    Gastroenterology; 2016 Jan; 150(1):218-228.e12. PubMed ID: 26408346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of CD44 attenuates aberrant GM-CSF signaling in Kras G12D hematopoietic progenitor/precursor cells and prolongs the survival of diseased animals.
    Du J; Liu Y; Meline B; Kong G; Tan LX; Lo JC; Wang J; Ranheim E; Zhang L; Chang YI; Ryu MJ; Zhang JF; Zhang J
    Leukemia; 2013 Mar; 27(3):754-7. PubMed ID: 22976127
    [No Abstract]   [Full Text] [Related]  

  • 16. Loss of Dnmt3a and endogenous Kras(G12D/+) cooperate to regulate hematopoietic stem and progenitor cell functions in leukemogenesis.
    Chang YI; You X; Kong G; Ranheim EA; Wang J; Du J; Liu Y; Zhou Y; Ryu MJ; Zhang J
    Leukemia; 2015 Sep; 29(9):1847-56. PubMed ID: 25801914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Krüppel-like Factor 5, Increased in Pancreatic Ductal Adenocarcinoma, Promotes Proliferation, Acinar-to-Ductal Metaplasia, Pancreatic Intraepithelial Neoplasia, and Tumor Growth in Mice.
    He P; Yang JW; Yang VW; Bialkowska AB
    Gastroenterology; 2018 Apr; 154(5):1494-1508.e13. PubMed ID: 29248441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of Capicua alters early T cell development and predisposes mice to T cell lymphoblastic leukemia/lymphoma.
    Tan Q; Brunetti L; Rousseaux MWC; Lu HC; Wan YW; Revelli JP; Liu Z; Goodell MA; Zoghbi HY
    Proc Natl Acad Sci U S A; 2018 Feb; 115(7):E1511-E1519. PubMed ID: 29382756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetically manipulating endogenous Kras levels and oncogenic mutations in vivo influences tissue patterning of murine tumorigenesis.
    Le Roux Ö; Pershing NLK; Kaltenbrun E; Newman NJ; Everitt JI; Baldelli E; Pierobon M; Petricoin EF; Counter CM
    Elife; 2022 Sep; 11():. PubMed ID: 36069770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice.
    Lyubynska N; Gorman MF; Lauchle JO; Hong WX; Akutagawa JK; Shannon K; Braun BS
    Sci Transl Med; 2011 Mar; 3(76):76ra27. PubMed ID: 21451123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.